| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| James P Madigan, Feng Hou, Linlei Ye, Jicheng Hu, Aiping Dong, Wolfram Tempel, Marielle E Yohe, Paul A Randazzo, Lisa M Miller Jenkins, Michael M Gottesman, Yufeng Ton. The tuberous sclerosis complex subunit TBC1D7 is stabilized by Akt phosphorylation-mediated 14-3-3 binding. The Journal of biological chemistry. vol 293. issue 42. 2019-03-20. PMID:30143532. |
the tuberous sclerosis complex (tsc) is a negative regulator of mtor complex 1, a signaling node promoting cellular growth in response to various nutrients and growth factors. |
2019-03-20 |
2023-08-13 |
Not clear |
| Paolo Curatolo, Romina Moavero, Jackelien van Scheppingen, Eleonora Aronic. mTOR dysregulation and tuberous sclerosis-related epilepsy. Expert review of neurotherapeutics. vol 18. issue 3. 2019-03-07. PMID:29338461. |
the robust mtor signaling deregulation observed in a large spectrum of epileptogenic developmental pathologies, such as focal cortical dysplasias and tuberous sclerosis complex (tsc), has been linked to germline and somatic mutations in mtor pathway regulatory genes, increasing the spectrum of 'mtoropathies'. |
2019-03-07 |
2023-08-13 |
Not clear |
| Yasuo Miki, Kunikazu Tanji, Fumiaki Mori, Jun Utsumi, Hidenao Sasaki, Akiyoshi Kakita, Hitoshi Takahashi, Koichi Wakabayash. Autophagy mediators (FOXO1, SESN3 and TSC2) in Lewy body disease and aging. Neuroscience letters. vol 684. 2019-02-20. PMID:29966750. |
transcriptional activation of foxo1 has been reported to initiate autophagy by inhibiting the expression of mechanistic target of rapamycin (mtor), mediated by sestrin 3 (sesn3) and tuberous sclerosis complex 2 (tsc2). |
2019-02-20 |
2023-08-13 |
mouse |
| Claudia Brandt, Petra Hillmann, Andreas Noack, Kerstin Römermann, Leon A Öhler, Denise Rageot, Florent Beaufils, Anna Melone, Alexander M Sele, Matthias P Wymann, Doriano Fabbro, Wolfgang Lösche. The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. Neuropharmacology. vol 140. 2019-02-20. PMID:30081001. |
clinical trials have shown that mtor inhibitors such as everolimus reduce seizures in tuberous sclerosis complex patients with intractable epilepsy. |
2019-02-20 |
2023-08-13 |
mouse |
| Ke Li, Hong He, Mao-Qing Hu, Lin Zhan. [Mechanism of Electropuncture for Reducing Diet-induced Obesity Rat Weight through Hypothala- mus TSC1 -mTOR Signal Pathway]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. vol 36. issue 7. 2019-02-18. PMID:30634218. |
to explore the mechanism of electropuncture (ea) for reducing diet-induced obesity (dio) rat weight through tuberous sclerosis complex 1 (tsc1 )-mammalian target of rapa- mycin (mtor) signal pathway in hypothalamus. |
2019-02-18 |
2023-08-13 |
rat |
| Darcy A Krueger, Jamie K Capal, Paolo Curatolo, Orrin Devinsky, Kevin Ess, Michal Tzadok, Mary K Koenig, Vinodh Narayanan, Federico Ramos, Sergiusz Jozwiak, Petrus de Vries, Anna C Jansen, Michael Wong, David Mowat, John Lawson, Stephanie Bruns, David Neal Fran. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. vol 22. issue 6. 2019-02-13. PMID:30005812. |
short-term safety of mtor inhibitors in infants and very young children with tuberous sclerosis complex (tsc): multicentre clinical experience. |
2019-02-13 |
2023-08-13 |
Not clear |
| Darcy A Krueger, Jamie K Capal, Paolo Curatolo, Orrin Devinsky, Kevin Ess, Michal Tzadok, Mary K Koenig, Vinodh Narayanan, Federico Ramos, Sergiusz Jozwiak, Petrus de Vries, Anna C Jansen, Michael Wong, David Mowat, John Lawson, Stephanie Bruns, David Neal Fran. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. vol 22. issue 6. 2019-02-13. PMID:30005812. |
to evaluate the safety of mtor inhibitors (sirolimus or everolimus) in infants and very young children with tuberous sclerosis complex (tsc) under two years of age. |
2019-02-13 |
2023-08-13 |
Not clear |
| Minqing Jiang, Rohit Rao, Jincheng Wang, Jiajia Wang, Lingli Xu, Lai Man Wu, Jonah R Chan, Huimin Wang, Q Richard L. The TSC1-mTOR-PLK axis regulates the homeostatic switch from Schwann cell proliferation to myelination in a stage-specific manner. Glia. vol 66. issue 9. 2019-02-12. PMID:29722913. |
we report here that tuberous sclerosis complex 1 (tsc1), a negative regulator of mtor activity, establishes a stage-dependent program for schwann cell lineage progression and myelination by controlling cell proliferation and myelin homeostasis. |
2019-02-12 |
2023-08-13 |
mouse |
| Marta Espinosa, Juan Maria Roldán-Romero, Ignacio Duran, Enrique de Álava, María Apellaniz-Ruiz, Alberto Cascón, Carmen Garrigos, Mercedes Robledo, Cristina Rodriguez-Anton. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation. BMC cancer. vol 18. issue 1. 2019-01-10. PMID:29764404. |
eaml can be sporadic or develop within the tuberous sclerosis complex syndrome, where mutations of tsc1 or tsc2 genes (critical negative regulators of mtor complex 1) result in an increased activation of mtor pathway. |
2019-01-10 |
2023-08-13 |
Not clear |
| Arnaud Jacquel, Frederic Luciano, Guillaume Robert, Patrick Auberge. Implication and Regulation of AMPK during Physiological and Pathological Myeloid Differentiation. International journal of molecular sciences. vol 19. issue 10. 2019-01-07. PMID:30274374. |
in addition, ampk inhibits the mtor pathway through phosphorylation and activation of tuberous sclerosis protein 2 (tsc2) and causes direct activation of unc-51-like autophagy activating kinase 1 (ulk1) via phosphorylation of ser555, thus promoting initiation of autophagy. |
2019-01-07 |
2023-08-13 |
Not clear |
| Jiheon Shin, Minhyung Kim, Hee-Jung Jung, Hye Lim Cha, Haeyoung Suh-Kim, Sanghyun Ahn, Jaehoon Jung, YounAh Kim, Yukyung Jun, Sanghyuk Lee, Daehee Hwang, Jaesang Ki. Characterization of developmental defects in the forebrain resulting from hyperactivated mTOR signaling by integrative analysis of transcriptomic and proteomic data. Scientific reports. vol 7. issue 1. 2018-12-18. PMID:28588230. |
hyperactivated mtor signaling in the developing brain has been implicated in multiple forms of pathology including tuberous sclerosis complex (tsc). |
2018-12-18 |
2023-08-13 |
Not clear |
| E N Imyanito. [Specific features of drug sensitivity of hereditary cancers]. Voprosy onkologii. vol 62. issue 2. 2018-12-11. PMID:30452211. |
tumors in patients with tuberous sclerosis often regress after administration of mtor inhibitors. |
2018-12-11 |
2023-08-13 |
Not clear |
| Kalpana Kumari, Mehar C Sharma, Aanchal Kakkar, Prit B Malgulwar, Pankaj Pathak, Vaishali Suri, Chitra Sarkar, Sarat P Chandra, Mohammed Faruq, Rakesh K Gupta, Ravindra K Sara. Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases. Neurology India. vol 64. issue 5. 2018-11-05. PMID:27625244. |
recent studies have shown that tuberous sclerosis complex (tsc) 1 and tsc2 genes are linked to the mammalian target of rapamycin (mtor) cell signaling pathway. |
2018-11-05 |
2023-08-13 |
Not clear |
| Denise L Chan, Tessa Calder, John A Lawson, David Mowat, Sean E Kenned. The natural history of subependymal giant cell astrocytomas in tuberous sclerosis complex: a review. Reviews in the neurosciences. vol 29. issue 3. 2018-10-31. PMID:29211682. |
tuberous sclerosis complex (tsc) is an auto-somal-dominant inherited condition with an incidence of approximately 1:6000 births, characterised by deregulated mtor activity with multi-site hamartomas. |
2018-10-31 |
2023-08-13 |
Not clear |
| Thomas Rosengren, Lasse Jonsgaard Larsen, Lotte Bang Pedersen, Søren Tvorup Christensen, Lisbeth Birk Mølle. TSC1 and TSC2 regulate cilia length and canonical Hedgehog signaling via different mechanisms. Cellular and molecular life sciences : CMLS. vol 75. issue 14. 2018-10-29. PMID:29396625. |
similarly, primary cilia have been implicated in regulation of mtor signaling, in which tuberous sclerosis complex proteins 1 and 2 (tsc1/2) negatively regulate protein synthesis by inactivating the mtor complex 1 (mtorc1) at energy limiting states. |
2018-10-29 |
2023-08-13 |
mouse |
| Meng-Na Zhang, Li-Ping Zou, Yang-Yang Wang, Ling-Yu Pang, Shu-Fang Ma, Lu-Lu Huang, Yang Gao, Qian Lu, David Neal Fran. Calcification in cerebral parenchyma affects pharmacoresistant epilepsy in tuberous sclerosis. Seizure. vol 60. 2018-10-15. PMID:29929111. |
tuberous sclerosis (tsc) is an autosomal dominant inherited disease caused by mutations in the tsc1 or tsc2 gene and results in the over-activation of the mammalian target of the rapamycin (mtor) signaling pathway. |
2018-10-15 |
2023-08-13 |
Not clear |
| Alice Polchi, Alessandro Magini, Danila Di Meo, Brunella Tancini, Carla Emilian. mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model. International journal of molecular sciences. vol 19. issue 5. 2018-09-26. PMID:29772672. |
mtor signaling and neural stem cells: the tuberous sclerosis complex model. |
2018-09-26 |
2023-08-13 |
Not clear |
| Hong-Mei Zhang, Vivian Diaz, Michael E Walsh, Yiqiang Zhan. Moderate lifelong overexpression of tuberous sclerosis complex 1 (TSC1) improves health and survival in mice. Scientific reports. vol 7. issue 1. 2018-09-18. PMID:28400571. |
the tuberous sclerosis complex 1/2 (tsc1/2) is an endogenous regulator of the mechanistic target of rapamycin (mtor). |
2018-09-18 |
2023-08-13 |
mouse |
| David L Kolin, Kai Duan, Bo Ngan, J Ted Gerstle, Monika K Krzyzanowska, Gino R Somers, Ozgur Met. Expanding the Spectrum of Colonic Manifestations in Tuberous Sclerosis: L-Cell Neuroendocrine Tumor Arising in the Background of Rectal PEComa. Endocrine pathology. vol 29. issue 1. 2018-08-27. PMID:28733877. |
neuroendocrine tumorigenesis in tuberous sclerosis is often linked to inactivating mutations of tsc2 leading to aberrant activation of mammalian target of rapamycin (mtor) pathway. |
2018-08-27 |
2023-08-13 |
Not clear |
| Fei Yang, Lingli Yang, Mari Wataya-Kaneda, Junya Hasegawa, Tamotsu Yoshimori, Atsushi Tanemura, Daisuke Tsuruta, Ichiro Katayam. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex. Journal of dermatological science. vol 89. issue 2. 2018-08-20. PMID:29146131. |
tuberous sclerosis complex (tsc) gene mutations lead to constitutive activation of the mammalian target of rapamycin (mtor) pathway, resulting in a broad range of symptoms. |
2018-08-20 |
2023-08-13 |
Not clear |